- Home
- CAPR
as 11-21-2024 4:00pm EST
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | BEVERLY HILLS |
| Market Cap: | 332.5M | IPO Year: | N/A |
| Target Price: | $39.29 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.07 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.90 - $23.40 | Next Earning Date: | 11-13-2024 |
| Revenue: | $23,228,045 | Revenue Growth: | 65.33% |
| Revenue Growth (this year): | -34.57% | Revenue Growth (next year): | 135.53% |
Stock Insider Trading Activity of Capricor Therapeutics Inc. (CAPR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Nippon Shinyaku Co Ltd | CAPR | 10% Owner | Sep 20 '24 | Buy | $5.36 | 2,798,507 | $14,999,997.52 | 7,090,351 |
Latest Capricor Therapeutics Inc. News
CAPR Breaking Stock News: Dive into CAPR Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
Capricor Gets Orphan Drug, Advanced Therapy Medicinal Product Designations for Deramiocel in Europe
GlobeNewswire
a day ago
Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency
MT Newswires
3 days ago
JonesTrading Initiates Capricor Therapeutics at Buy Rating With $40 Price Target
Insider Monkey
6 days ago
Is Capricor Therapeutics (CAPR) the Best Multibagger Stock to Buy Heading into 2025?
Simply Wall St.
6 days ago
Capricor Therapeutics Third Quarter 2024 Earnings: Misses Expectations
Thomson Reuters StreetEvents
7 days ago
Q3 2024 Capricor Therapeutics Inc Earnings Call
Zacks
8 days ago
Capricor Therapeutics (CAPR) Reports Q3 Loss, Misses Revenue Estimates
MT Newswires
8 days ago
Capricor Therapeutics Q3 Net Loss Widens, Revenue Declines From Year-Ago Levels
Compare CAPR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CAPR Capricor Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.